Clinical Trial Update: A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating two formulations of LEO 43204 for actinic keratosis has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LEO 43204 - Formula 1
• LEO 43204 - Formula 2

Snippet

Sponsor: LEO Pharma | Conditions: Actinic Keratosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-27